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See related research by Palazzuoli et al., http://ccforum.com/content/18/3/R134Palazzuoli and colleagues report on a study comparing
continuous versus bolus infusion of furosemide in acute
decompensated heart failure [1]. Patients in the continu-
ous infusion group had greater urine output, decreased
renal function and increased 6-month mortality.
We feel that, due to the study design, the conclusions
drawn are difficult to translate into clinical practice. The
decisive advantage of continuous over bolus infusion is the
ability to titrate to effect in a gradual and precise manner.
This advantage is completely negated when large-step (that
is, doubling) dose increases are rigidly protocolized, as was
the case in this study. When the advantages of a method
are lost, only its comparative harms remain: continuous
infusion may have a stronger diuretic effect than bolus
infusion (milligram for milligram) [2] and the continuous* Correspondence: h.degrooth@vumc.nl
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article, unless otherwise stated.infusion group in this study seemed overtreated, resulting
in renal dysfunction that is associated with poor out-
comes [3].
Future research should focus on the optimal method to
attain the clinical goal of inducing sufficient but not exces-
sive diuresis. Comparing outcomes on a protocolized-dose
basis is straightforward but cannot elucidate which me-
thod is best in practice. Indeed, the authors write that a
study utilizing a more tailored dose could further clarify
this subject. We suggest that a truly relevant comparison
can only be made when treatment in both groups is aimed
at individual targets. This would require a large trial with
patients optimally treated using either of the two infusion
methods, while dosing is completely determined by preset
clinically relevant endpoints.Alberto Palazzuoli and Gaetano Ruocco
We thank de Grooth and colleagues for their observation.
We partially agree with their statements for at least three
principal reasons. First, the impact of worsening renal
function (WRF) was recently questioned and data from the
ESCAPE trial [4], as well as other recent studies, revealed
that baseline renal dysfunction but not WRF is related to
poor outcome. Secondly, the temporal trend of WRF ap-
pears to have a better prognostic significance; in fact, tran-
sient or persistent WRF seems to show different impact in
terms of outcome [5]. In our study we only measured renal
function changes during hospitalization and not after dis-
charge. Finally, in our analysis we did not evaluate signs of
congestion, so the relation among overdiuresis/deconges-
tion and WRF/adverse events could only be supposed [1].However, worse diuretic response is associated with more
advanced heart failure, renal dysfunction and poor out-
come [6]. It is therefore hard to establish whether impaired
renal function is the ‘egg’ or the ‘chicken’.
Instead we agree with the advice that a fixed diuretic
administration is far from perfect and its dosing and modal-
ity infusion should be adjusted for each patient on the basis
of clinical signs, laboratory biomarkers (renal function,
hemoconcentration, plasma osmolarity) and kidney im-
aging. Overall, a guideline standardized method does not
currently exist, and therefore all previous studies employed
fixed protocols. We indeed propose a more consistent clin-
ical approach measuring daily urine output and weight loss.
Better assessment of systemic congestion considering
perfusion, neuroendocrine activation and fluid redistri-
bution could lead to a better understanding of diuretic
therapy administration.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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